Cardiovascular complications represent the leading cause of morbidity and premature mortality among individuals living with metabolic disorders. Consequently, modern clinical practice emphasizes the prompt initiation of cardioprotective therapy in diabetes to improve long-term survival. International cardiology guidelines advise clinicians to prescribe organ-protective agents regardless of baseline glycemic levels. However, real-world translation of these recommendations often faces persistent clinical inertia across routine outpatient cardiology settings.

The Burden of Cardiovascular Disease in Type 2 Diabetes

Type 2 diabetes accelerates macrovascular atherogenesis and causes profound myocardial injury over time. Therefore, individuals with diabetes experience elevated rates of coronary artery disease, ischemic stroke, and heart failure. Epidemiological surveys consistently show that cardiovascular complications drive most hospital admissions in this population. Furthermore, diabetic cardiomyopathy often develops insidiously, creating left ventricular remodeling before overt symptoms appear. In addition, diabetic nephropathy frequently coexists with cardiac dysfunction, creating a dangerous cardiorenal cycle. Because these pathological mechanisms act synergistically, traditional glucose control alone cannot prevent cardiovascular mortality. Cardiologists routinely evaluate these vulnerable patients during everyday clinical visits. Consequently, cardiovascular specialists occupy a pivotal position to initiate organ-protective therapies. Therefore, clinical guidelines recommend comprehensive risk factor reduction rather than isolated glycemic targets. Proactive medical management during outpatient consultations significantly reduces downstream vascular events. Moreover, early intervention prevents catastrophic decompensation and preserves vital functional capacity. Clinical teams must prioritize evidence-based protocols during every ambulatory contact. Consequently, multidisciplinary care models ensure that every high-risk patient receives guideline-recommended interventions promptly.

Evaluating Cardioprotective Therapy in Diabetes: The CardioMET Registry

The multicenter Italian CardioMET registry investigated guideline-directed prescribing patterns in 2,527 consecutive outpatients with diabetes between 2022 and 2025. Notably, researchers reported that 70.7% of participants had established atherosclerotic cardiovascular disease. In addition, 86.1% of patients without established atherosclerosis fell into high or very high cardiovascular risk categories. Documented heart failure affected 48.9% of individuals with available diagnostic data. These baseline metrics illustrate the profound vulnerability of patients attending specialized outpatient cardiology clinics. Despite clear guideline indications, sodium-glucose co-transporter-2 inhibitors were prescribed to only 42.2% of the total cohort. Furthermore, glucagon-like peptide-1 receptor agonists showed an even lower utilization rate of 27.7%. Combination therapy utilizing both drug classes occurred in merely 14.8% of patients. Consequently, these findings highlight a striking gap between published scientific evidence and daily medical practice. Many vulnerable individuals remain unprotected despite attending specialty clinics. Outpatient cardiologists must recognize this treatment deficit to improve clinical outcomes across the spectrum of cardiometabolic disease. Moreover, real-world registries bridge critical knowledge deficits and help clinicians evaluate their own institutional prescribing behaviors.

Prescription Disparities Between SGLT2 Inhibitors and GLP-1 RAs

The CardioMET registry demonstrated significant differences in prescribing patterns between drug classes. Specifically, cardiologists initiated sodium-glucose co-transporter-2 inhibitors far more frequently in patients with confirmed atherosclerotic disease than in high-risk patients without atherosclerosis. In contrast, glucagon-like peptide-1 receptor agonists showed persistent underutilization regardless of cardiovascular history. Cardiologists generally demonstrate greater comfort prescribing gliflozins because prominent heart failure clinical trials established clear cardiological indications. Furthermore, once-daily oral administration simplifies treatment regimens for both clinicians and patients. Conversely, many cardiovascular specialists still perceive glucagon-like peptide-1 receptor agonists primarily as glycemic tools. Injectable delivery devices and prior authorization requirements frequently discourage cardiologists from initiating these therapies. In addition, concerns regarding gastrointestinal intolerance often create therapeutic inertia during brief clinic visits. However, expanding clinical trial data proves that both medication classes deliver complementary vascular and metabolic benefits. Therefore, medical teams must abandon historical drug hierarchies and prescribe both classes proactively to achieve maximum risk reduction. In addition, contemporary clinical trials demonstrate substantial reductions in major vascular events when clinicians combine both drug classes.

Predictors of Non-Prescription and Systemic Barriers

Multivariable logistic regression in the CardioMET study revealed key factors predicting therapeutic omission. Advanced age and female sex strongly correlated with non-prescription of cardioprotective therapies. In addition, preserved renal function paradoxically reduced the odds of receiving sodium-glucose co-transporter-2 inhibitors in specific clinical subsets. Clinicians frequently hesitate to initiate newer therapies in older patients due to fears of adverse drug interactions and dehydration. Similarly, clinical inertia prevents timely drug modification during standard ambulatory checkups. Many physicians focus exclusively on hemoglobin A1c thresholds instead of organ protection. Furthermore, cumbersome administrative paperwork and economic constraints restrict medication adoption across outpatient centers. Consequently, many patients continue using older agents that provide no cardiovascular mortality benefit. Overcoming these barriers requires standardized institutional guidelines and automated clinical decision support systems within electronic medical records. Moreover, specialized nurse-led clinics can educate patients, monitor tolerance, and streamline treatment initiation. By eliminating administrative roadblocks, health systems can empower clinicians to implement guideline-directed medical therapy consistently. Furthermore, ongoing professional development programs ensure that clinical teams stay informed about rapidly evolving international cardiology guidelines.

Translating CardioMET Insights to Clinical Practice in India

The findings of the CardioMET registry offer vital lessons for healthcare professionals across India. South Asian patients typically develop type 2 diabetes at younger ages and exhibit extensive, premature atherosclerotic disease. Furthermore, the combination of diabetes and heart failure imposes an enormous clinical burden on the Indian healthcare infrastructure. Although Indian clinical guidelines strongly advocate for early cardiorenal protection, real-world prescribing faces unique economic and operational challenges. Fortunately, the widespread availability of cost-effective generic sodium-glucose co-transporter-2 inhibitors has expanded therapeutic access nationwide. However, the higher cost of glucagon-like peptide-1 receptor agonists continues to limit broad adoption in routine practice. Therefore, Indian cardiologists, consulting physicians, and endocrinologists must collaborate through joint cardiometabolic clinics. Such collaborative models facilitate comprehensive risk assessment and promote timely initiation of evidence-based therapies. Additionally, clinical teams must actively educate patients regarding the proven cardiovascular benefits of these agents. Ultimately, proactive prescribing in outpatient environments will reduce preventable cardiovascular mortality across India.

Frequently Asked Questions

Why is cardioprotective therapy underprescribed in outpatient cardiology clinics?

Cardioprotective therapy remains underprescribed largely because of clinical inertia, concerns about polypharmacy, and administrative burdens. Many cardiologists still consider blood sugar management the exclusive responsibility of endocrinologists. Furthermore, unfamiliarity with dosing schedules and potential adverse effects creates prescribing hesitation during brief consultations. To overcome these common barriers, professional societies advocate for integrated care pathways, automated medical record reminders, and continuing medical education for practicing clinicians.

Which patients with diabetes benefit most from combining SGLT2i and GLP-1 RA?

Patients living with type 2 diabetes who present with coexisting atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease benefit most from combination therapy. Combining sodium-glucose co-transporter-2 inhibitors with glucagon-like peptide-1 receptor agonists delivers complementary therapeutic actions. Specifically, this dual approach lowers major adverse cardiovascular events, prevents heart failure hospitalizations, and retards chronic kidney disease progression. Therefore, current international guidelines recommend dual cardioprotective therapy for individuals at very high risk.

How do contemporary guidelines prioritize cardioprotective therapies over glycemic targets?

Major clinical guidelines, including recommendations from the European Society of Cardiology and the American Diabetes Association, prioritize organ protection over glycemic thresholds. Clinicians should select sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists based on established cardiovascular risk rather than baseline glycated hemoglobin. Consequently, these agents serve as foundational secondary prevention therapies for patients with established cardiovascular disease, heart failure, or renal impairment, independent of glucose levels.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment when interpreting and applying this information. Clinical guidelines and prescribing practices vary across countries and healthcare systems. Refer to the latest local and national guidelines for clinical practice.

References

1. Gargiulo P et al. Implementation of guideline-directed cardioprotective therapy in patients living with type 2 diabetes in outpatient cardiology ambulatory setting: the Italian CardioMET registry. Eur J Intern Med. 2026 Oct 05. doi: undefined. PMID: 42833986.
2. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140.
3. ElSayed NA, Aleppo G, Aroda VR, et al. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S179-S218.